Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

India CRO Market

ID: MRFR/Pharma/2151-HCR
70 Pages
Satyendra Maurya
Last Updated: April 24, 2026

์ธ๋„ CRO ์‹œ์žฅ ์กฐ์‚ฌ ๋ณด๊ณ ์„œ - 2032๋…„๊นŒ์ง€ ์ „๋ง

๊ณต์œ 
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

India CRO Market Infographic
Purchase Options
  1. 1 ์„œ๋ก 
    1. 1.1 ์ •์˜
    2. 1.2 ์—ฐ๊ตฌ ๋ฒ”์œ„
    3. 1.3 ์—ฐ๊ตฌ ๋ชฉํ‘œ
    4. 1.4 ๊ฐ€์ • ๋ฐ ์ œํ•œ ์‚ฌํ•ญ
    5. 1.5 ์‹œ์žฅ ๊ตฌ์กฐ:
  2. 2 ์—ฐ๊ตฌ ๋ฐฉ๋ฒ•๋ก 
    1. 2.1 ์—ฐ๊ตฌ ํ”„๋กœ์„ธ์Šค
    2. 2.2 1์ฐจ ์—ฐ๊ตฌ
    3. 2.3 2์ฐจ ์—ฐ๊ตฌ
  3. 3 ์‹œ์žฅ ์—ญํ•™
    1. 3.1 ๋™์ธ
    2. 3.2 ์ œ์•ฝ
    3. 3.3 ๊ธฐํšŒ
    4. 3.4 ๊ณผ์ œ
    5. 3.5 ๊ฑฐ์‹œ๊ฒฝ์ œ ์ง€ํ‘œ
  4. 4 ์‹œ์žฅ ์š”์ธ ๋ถ„์„
    1. 4.1 ํฌํ„ฐ์˜ 5๊ฐ€์ง€ ํž˜ ๋ชจ๋ธ
      1. 4.1.1 ๊ณต๊ธ‰์—…์ฒด์˜ ํ˜‘์ƒ๋ ฅ
      2. 4.1.2 ๊ณ ๊ฐ์˜ ํ˜‘์ƒ๋ ฅ
      3. 4.1.3 ๊ฒฝ์Ÿ์—…์ฒด์˜ ๊ฐ•๋„
      4. 4.1.4 ์‹ ๊ทœ ์ง„์ž…์ž์˜ ์œ„ํ˜‘
  5. 5 ์„œ๋น„์Šค ์œ ํ˜•๋ณ„ ์ธ๋„ CRO ์‹œ์žฅ
    1. 5.1 ์„œ๋ก 
      1. 5.1.1 ์ž„์ƒ ์‹œํ—˜
      2. 5.1.2 ์ œํ’ˆ ๊ฐœ๋ฐœ
      3. 5.1.3 ๊ณต์ • ๊ฐœ๋ฐœ
      4. 5.1.4 ์‹œํŒ โ€‹โ€‹ํ›„ ๊ฐ์‹œ
      5. 5.1.5 ํ’ˆ์งˆ ๋ชจ๋‹ˆํ„ฐ๋ง
      6. 5.1.6 ๊ธฐํƒ€
  6. 6 ์น˜๋ฃŒ ์‘์šฉ ๋ถ„์•ผ๋ณ„ ์ธ๋„ CRO ์‹œ์žฅ
    1. 6.1 ์„œ๋ก 
      1. 6.1.1 ์ข…์–‘ํ•™
      2. 6.1.2 ์‹ฌํ˜ˆ๊ด€
      3. 6.1.3 ์‹ ๊ฒฝํ•™
      4. 6.1.4 ์‹ ์žฅํ•™ ๋ฐ ๋น„๋‡จ๊ธฐ๊ณผ
      5. 6.1.5 ์‹ฌํ˜ˆ๊ด€
      6. 6.1.6 ๊ธฐํƒ€
  7. 7 ์ตœ์ข… ์‚ฌ์šฉ์ž๋ณ„ ์ธ๋„ CRO ์‹œ์žฅ
    1. 7.1 ์„œ๋ก 
      1. 7.1.1 ์ œ์•ฝ/์ƒ๋ฌผ ์ œ์•ฝ ํšŒ์‚ฌ
      2. 7.1.3 ์˜๋ฃŒ ๊ธฐ๊ธฐ ํšŒ์‚ฌ
      3. 7.1.4 ํ•™์ˆ  ๊ธฐ๊ด€
  8. 8 ๊ตญ๊ฐ€๋ณ„ ์ธ๋„ CRO ์‹œ์žฅ
    1. 8.1 ์†Œ๊ฐœ
    2. 8.2 ๋ถ์ธ๋„
    3. 8.3 ๋‚จ์ธ๋„
    4. 8.4 ๋™์ธ๋„
    5. 8.5 ์„œ์ธ๋„
    6. 8.6 ์ค‘๋ถ€ ์ธ๋„
  9. 9 ํšŒ์‚ฌ ํ˜„ํ™ฉ
    1. 9.1 ์†Œ๊ฐœ
      1. 9.1.1 ํ•ฉ๋ณ‘ ์ธ์ˆ˜
      2. 9.1.2 ํ˜‘์—…
      3. 9.1.3 ์ถœ์‹œ/์‹ ์ œํ’ˆ ์ถœ์‹œ
      4. 9.1.4 ๊ธฐํƒ€(ํ™•์žฅ, ์—…๋ฐ์ดํŠธ, ํŒŒํŠธ๋„ˆ์‹ญ)
  10. 10 ํšŒ์‚ฌ ํ”„๋กœํ•„
    1. 10.1 Quintiles IMS Holdings, Inc.
      1. 10.1.1 ํšŒ์‚ฌ ๊ฐœ์š”
      2. 10.1.2 ์ œํ’ˆ/์‚ฌ์—… ๋ถ€๋ฌธ ๊ฐœ์š”
      3. 10.1.3 ์žฌ๋ฌด
      4. 10.1.4 ์ฃผ์š” ๊ฐœ๋ฐœ ์‚ฌํ•ญ
      5. 10.1.5 SWOT ๋ถ„์„
    2. 10.2 Syngene, Pharmaceutical Product Development, LLC
      1. 10.2.1 ๊ฐœ์š”
      2. 10.2.2 ์ œํ’ˆ/์‚ฌ์—… ๋ถ€๋ฌธ ๊ฐœ์š”
      3. 10.2.3 ์žฌ๋ฌด
      4. 10.2.4 ์ฃผ์š” ๊ฐœ๋ฐœ ์‚ฌํ•ญ
      5. 10.2.5 SWOT ๋ถ„์„
    3. 10.3 Siro Clinpharm
      1. 10.3.1 ๊ฐœ์š”
      2. 10.3.2 ์ œํ’ˆ/์‚ฌ์—… ๋ถ€๋ฌธ ๊ฐœ์š”
      3. 10.3.3 ์žฌ๋ฌด
      4. 10.3.4 ์ฃผ์š” ๊ฐœ๋ฐœ ์‚ฌํ•ญ
      5. 10.3.5 SWOT ๋ถ„์„
    4. 10.4 VIMTA, Bilcare Limited
      1. 10.4.1 ๊ฐœ์š”
      2. 10.4.2 ์ œํ’ˆ/์‚ฌ์—… ๋ถ€๋ฌธ ๊ฐœ์š”
      3. 10.4.3 ์žฌ๋ฌด ์ •๋ณด
      4. 10.4.4 ์ฃผ์š” ๊ฐœ๋ฐœ ์‚ฌํ•ญ
      5. 10.4.5 SWOT ๋ถ„์„
    5. 10.5 Aizant Drug Research Solutions Private Limited
      1. 10.5.1 ๊ฐœ์š”
      2. 10.5.2 ์ œํ’ˆ/์‚ฌ์—… ๋ถ€๋ฌธ ๊ฐœ์š”
      3. 10.5.3 ์žฌ๋ฌด ์ •๋ณด
      4. 10.5.4 ์ฃผ์š” ๊ฐœ๋ฐœ ์‚ฌํ•ญ
      5. 10.5.5 SWOT ๋ถ„์„
    6. 10.6 Piramal Pharma Solutions
      1. 10.6.1 ๊ฐœ์š”
      2. 10.6.2 ์ œํ’ˆ/์‚ฌ์—… ๋ถ€๋ฌธ ๊ฐœ์š”
      3. 10.6.3 ์žฌ๋ฌด ์ •๋ณด
      4. 10.6.4 ์ฃผ์š” ๊ฐœ๋ฐœ ์‚ฌํ•ญ
      5. 10.6.5 SWOT ๋ถ„์„
    7. 10.7 Synapse Labs Pvt ์ œํ•œ์ 
      1. 10.7.1 ๊ฐœ์š”
      2. 10.7.2 ์ œํ’ˆ/์‚ฌ์—… ๋ถ€๋ฌธ ๊ฐœ์š”
      3. 10.7.3 ์žฌ๋ฌด ์ •๋ณด
      4. 10.7.4 ์ฃผ์š” ๊ฐœ๋ฐœ ์‚ฌํ•ญ
      5. 10.7.5 SWOT ๋ถ„์„
    8. 10.8 Eurofins Scientific
      1. 10.8.1 ๊ฐœ์š”
      2. 10.8.2 ์ œํ’ˆ/์‚ฌ์—… ๋ถ€๋ฌธ ๊ฐœ์š”
      3. 10.8.3 ์žฌ๋ฌด ์ •๋ณด
      4. 10.8.4 ์ฃผ์š” ๊ฐœ๋ฐœ ์‚ฌํ•ญ
      5. 10.8.5 SWOT ๋ถ„์„
    9. 10.9 Laurus Labs., Neuland Laboratories Ltd
      1. 10.9.1 ๊ฐœ์š”
      2. 10.9.2 ์ œํ’ˆ/์‚ฌ์—… ๋ถ€๋ฌธ ๊ฐœ์š”
      3. 10.9.3 ์žฌ๋ฌด ์ •๋ณด
      4. 10.9.4 ์ฃผ์š” ๊ฐœ๋ฐœ ์‚ฌํ•ญ
      5. 10.9.5 SWOT ๋ถ„์„
    10. 10.10 PAREXEL International Corporation
      1. 10.10.1 ๊ฐœ์š”
      2. 10.10.2 ์ œํ’ˆ/์‚ฌ์—… ๋ถ€๋ฌธ ๊ฐœ์š”
      3. 10.10.3 ์žฌ๋ฌด ์ •๋ณด
      4. 10.10.4 ์ฃผ์š” ๊ฐœ๋ฐœ ์‚ฌํ•ญ
      5. 10.10.5 SWOT ๋ถ„์„
    11. 10.11 ๊ธฐํƒ€
  11. 11 ๋ถ€๋ก
    1. ํ‘œ ๋ชฉ๋ก
    2. ํ‘œ 1 ์ธ๋„ CRO ์‹œ์žฅ, 2020-2032๋…„(10์–ต ๋‹ฌ๋Ÿฌ)
    3. ํ‘œ 2 ์„œ๋น„์Šค ์œ ํ˜•๋ณ„ ์ธ๋„ CRO ์‹œ์žฅ, 2020-2032๋…„(10์–ต ๋‹ฌ๋Ÿฌ)
    4. ํ‘œ 3 ์น˜๋ฃŒ์  ์ ์šฉ๋ณ„ ์ธ๋„ CRO ์‹œ์žฅ, 2020-2032๋…„(10์–ต ๋‹ฌ๋Ÿฌ) 10์–ต ๋‹ฌ๋Ÿฌ)
    5. ํ‘œ 4 ์ตœ์ข… ์‚ฌ์šฉ์ž๋ณ„ ์ธ๋„ CRO ์‹œ์žฅ, 2020-2032๋…„(10์–ต ๋‹ฌ๋Ÿฌ)
    6. ํ‘œ 5 ์ง€์—ญ๋ณ„ ์ธ๋„ CRO ์‹œ์žฅ, 2020-2032๋…„(10์–ต ๋‹ฌ๋Ÿฌ)
    7. ๊ทธ๋ฆผ ๋ชฉ๋ก
    8. ๊ทธ๋ฆผ 1 ์—ฐ๊ตฌ ํ”„๋กœ์„ธ์Šค
    9. ๊ทธ๋ฆผ 2 ํฌํ„ฐ์˜ 5๊ฐ€์ง€ ํž˜ ๋ชจ๋ธ
    10. ๊ทธ๋ฆผ 3 ์„œ๋น„์Šค ์œ ํ˜•๋ณ„ ์ธ๋„ CRO ์‹œ์žฅ
    11. ๊ทธ๋ฆผ 4 ์น˜๋ฃŒ ์‘์šฉ ๋ถ„์•ผ๋ณ„ ์ธ๋„ CRO ์‹œ์žฅ
    12. ๊ทธ๋ฆผ 5 ์ตœ์ข… ์‚ฌ์šฉ์ž๋ณ„ ์ธ๋„ CRO ์‹œ์žฅ
    13. ๊ทธ๋ฆผ 6 ์ง€์—ญ๋ณ„ ์ธ๋„ CRO ์‹œ์žฅ ์ง€์—ญ
    14. ๊ทธ๋ฆผ 7 ์ธ๋„ CRO ์‹œ์žฅ: ํšŒ์‚ฌ ์ ์œ ์œจ ๋ถ„์„, 2023(%)

์‹œ์žฅ ์„ธ๋ถ„ํ™”

์ธ๋„ CRO ์‹œ์žฅ ์„œ๋น„์Šค ์œ ํ˜• ์ „๋ง(10์–ต ๋‹ฌ๋Ÿฌ, 2018-2032๋…„)

  • ์ž„์ƒ ์‹œํ—˜

  • ์ œํ’ˆ ๊ฐœ๋ฐœ

  • ๊ณต์ • ๊ฐœ๋ฐœ

  • ์‹œํŒ ํ›„ ๊ฐ์‹œ

  • ํ’ˆ์งˆ ๋ชจ๋‹ˆํ„ฐ๋ง ๊ธฐํƒ€

์ธ๋„ CRO ์‹œ์žฅ ์‘์šฉ ์ „๋ง(10์–ต ๋‹ฌ๋Ÿฌ, 2018-2032)

  • ์ข…์–‘ํ•™

  • ์‹ฌํ˜ˆ๊ด€ํ•™

  • ์‹ ๊ฒฝํ•™

  • ์‹ ์žฅํ•™

  • ๋น„๋‡จ๊ธฐ๊ณผ

  • ๊ธฐํƒ€

์ธ๋„ CRO ์‹œ์žฅ ์ตœ์ข… ์‚ฌ์šฉ์ž ์ „๋ง(10์–ต ๋‹ฌ๋Ÿฌ, 2018-2032)

  • ์ œ์•ฝ/๋ฐ”์ด์˜ค ์ œ์•ฝ ํšŒ์‚ฌ

  • ์˜๋ฃŒ๊ธฐ๊ธฐ ํšŒ์‚ฌ

  • ํ•™์ˆ  ๊ธฐ๊ด€

Case Study Cover Image
์‚ฌ๋ก€ ์—ฐ๊ตฌ

Aerospace & Defense

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization โœ“ โœ“ โœ“
Direct Access to Analyst โœ“ โœ“ โœ“
Deliverable Format โœ“ โœ“ โœ“
Platform Access โœ— โœ— โœ“
Discount on Next Purchase 10% 15% 15%
Printable Versions โœ— โœ— โœ“